

NEWS RELEASE

SHELDON INWENTASH AND JOINT ACTORS ACQUIRES SECURITIES OF IMAGINATION PARK ENTERTAINMENT INC.

Toronto, Ontario, November 9, 2018 – Sheldon Inwentash (“Inwentash”) announces that his joint actors (the “Joint Actors”) have acquired ownership and control of an aggregate of 7,750,000 common shares (the “Subject Shares”) and 7,750,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Imagination Park Entertainment Inc. (the “Company”) on November 9, 2018. The Subject Units represented approximately 7.6% of all issued and outstanding common shares of the Company as of November 9, 2018 immediately following the transaction described above (or approximately 14.2% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by the Joint Actors as a result of the transaction.

Immediately before the transaction described above, Inwentash and the Joint Actors held an aggregate of 2,600,000 common shares of the Company (the “Pre-Shares”), and convertible securities entitling Inwentash and the Joint Actors to acquire an additional 5,400,000 common shares of the Company (the “Pre-Convertible Securities”) representing approximately 3.4% of the issued and outstanding common shares of the Company (or approximately 9.8% on a partially diluted basis, assuming exercise of the Pre-Convertible Securities only). Of this total, Inwentash held an aggregate of nil of the Pre-Shares and 1,000,000 Pre-Convertible Securities, representing approximately 0.0% of the issued and outstanding common shares of the Company (or approximately 1.3% assuming exercise of such Pre-Convertible Securities only), and the Joint Actors held an aggregate of 2,600,000 of the Pre-Shares and 4,400,000 Pre-Convertible Securities, representing approximately 3.4% of the issued and outstanding common shares of the Company (or approximately 8.7% assuming exercise of such Pre-Convertible Securities only).

Immediately following the transaction described above, Inwentash and the Joint Actors held an aggregate of 10,350,000 common shares (the “Post-Shares”) and convertible securities entitling Inwentash and the Joint Actors to acquire an additional 13,150,000 common shares of the Company (the “Post-Convertible Securities”), representing approximately 10.2% of the issued and outstanding common shares of the Company (or approximately 20.5% assuming exercise of such Post-Convertible Securities only). Of this total, Inwentash held an aggregate of 2,500,000 of the Post-Shares and 3,500,000 of the Post-Convertible Securities (representing approximately 2.5% of the issued and outstanding common shares of the Company or approximately 5.8% assuming exercise of such Post-Convertible Securities only), and the Joint Actors held an aggregate of 7,850,000 of the Post-Shares and 9,650,000 of the Post-Closing Convertible Securities (representing approximately 7.7% of the issued and outstanding common shares of the Company, or approximately 15.7% assuming exercise of such Post-Convertible Securities only).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange. The holdings of securities of the Company by Inwentash and the Joint Actors are managed for investment purposes, and Inwentash and the Joint Actors could increase or decrease their investments in the Company at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was \$930,000, or \$0.12 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of Inwentash and the Joint Actors are an “accredited investor” as defined herein.

Additional Information

A copy of the applicable securities report filed in connection with the matters set forth above may be obtained by contacting:

Sheldon Inwentash
69 Yonge St., Suite 1010
Toronto, ON, M5E 1K3

Tel: 416-941-8900